This is a multicenter, single arm, phase 2 study designed to evaluate the efficacy and safety
of cetuximab for the treatment of advanced (unresectable)/metastatic, chordoma. The target
patient population will be any chordoma patient 18 years of age with locally unresectable
disease or metastatic disease.
• To evaluate the efficacy of cetuximab in patients with advanced (unresectable) or
metastatic, chordoma based on response rate according to RECIST1.1.
To evaluate response rate according to Choi criteria
To evaluate the safety and tolerability of cetuximab for chordoma patients
To evaluate the progression-free survival (median, at 24 weeks, and 52 weeks) and to
determine the overall survival (median).
To evaluate the ratio of PFS on study compared to PFS from prior treatment
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.